Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiferon plus ribavirin versus pegylated interferon alfa-2a plus ribavirin in prior non-responder genotype 1 hepatitis C
2009-018146-38Phase 3Active
- Sponsor
- Sobi
- Start
- Mar 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of interferon alfa and ribavirin in hepatitis C virus infection (2 arms), sponsored by Sobi. Primary endpoint: Complete early viral response. Started Mar 2010; status: active.
02
Drugs
interferon alfaribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-018146-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018146-38.